文献速递肝病消化道肿瘤与早癌

慢性乙型肝炎基线病毒载量与治疗期间肝细胞癌风险的非线性关联

Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B.
PubMed 文献 · Gut · 2024-03-07

这项多中心历史队列研究纳入4693例无肝硬化的成人慢性乙型肝炎患者,评估基线HBV DNA水平与治疗期间肝细胞癌风险的关系。中位7.6年抗病毒治疗期间193例发生肝细胞癌(0.53/100人年)。基线病毒载量与肝细胞癌风险呈非线性抛物线关联,中等病毒载量(5.00-7.99 log10 IU/mL)风险最高(HR 2.60,p<0.001),高病毒载量(≥8.00 log10 IU/mL)风险最低。

要点

  • 基线HBV DNA 5.00-7.99 log10 IU/mL组肝细胞癌风险最高(HR 2.60,p<0.001)。
  • 基线HBV DNA 6.00-6.99 log10 IU/mL组风险最高(HR 3.36,p<0.001),对比≥8.00 log10 IU/mL组。
  • 基线高病毒载量(≥8.00 log10 IU/mL)患者治疗期间肝细胞癌风险最低。

核心结论

  • 基线中等病毒载量、尤其约6 log10 IU/mL的患者,尽管长期抗病毒治疗,治疗期间肝细胞癌风险最高。
  • 作者认为应考虑根据病毒载量早期启动抗病毒治疗,以降低无肝硬化成人慢性乙型肝炎患者的肝细胞癌风险。

研究设计与样本

  • 多中心历史队列研究,纳入4693例无肝硬化的成人慢性乙型肝炎患者,包括HBeAg阴性和HBeAg阳性、启动抗病毒治疗者。
  • 以基线HBV病毒载量作为分类变量估计肝细胞癌风险。

主要发现

  • 中位7.6年抗病毒治疗期间,193例患者发生肝细胞癌(0.53/100人年)。
  • 基线HBV DNA水平与治疗期间肝细胞癌风险独立相关,呈非线性抛物线模式。
  • 中等基线病毒载量(5.00-7.99 log10 IU/mL)患者肝细胞癌风险最高(HR 2.60,p<0.001)。
  • 低病毒载量(3.30-4.99 log10 IU/mL)患者HR 1.66(p=0.11)。
  • 高病毒载量(≥8.00 log10 IU/mL)患者肝细胞癌风险最低;基线HBV DNA 6.00-6.99 log10 IU/mL患者相比≥8.00 log10 IU/mL者HR 3.36(p<0.001)。

临床怎么用

  • 作者认为应考虑根据病毒载量早期启动抗病毒治疗,以降低无肝硬化成人慢性乙型肝炎患者的肝细胞癌风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The association between baseline pretreatment serum HBV DNA levels and on-treatment hepatocellular carcinoma (HCC) risk remains controversial in patients with chronic hepatitis B (CHB). We aimed to investigate the association between baseline HBV viral load and on-treatment HCC risk in CHB patients without cirrhosis. DESIGN: Using a multicentre historical cohort study including 4693 hepatitis B e antigen (HBeAg)-negative and HBeAg-positive, adult CHB patients without cirrhosis who initiated antiviral treatment, HCC risk was estimated by baseline HBV viral load as a categorical variable. RESULTS: During a median of 7.6 years of antiviral treatment, 193 patients developed HCC (0.53 per 100 person- years). Baseline HBV DNA level was independently associated with on-treatment HCC risk in a non-linear, parabolic pattern. Patients with moderate baseline viral loads (5.00-7.99 log10 IU/mL) exhibited the highest HCC risk (HR, 2.60; p<0.001), followed by those with low viral loads (3.30-4.99 log10 IU/mL; HR, 1.66; p=0.11). Patients with high viral loads (≥8.00 log10 IU/mL) presented the lowest HCC risk. Particularly, patients with baseline HBV DNA levels 6.00-6.99 log10 IU/mL had the highest on-treatment HCC risk (HR, 3.36; p<0.001) compared with those with baseline HBV DNA levels≥8.00 log10 IU/mL. These findings were more prominent among HBeAg-positive patients, younger patients, or those with less advanced hepatic fibrosis. CONCLUSION: Patients with moderate baseline viral load, particularly around 6 log10 IU/mL, demonstrated the highest on-treatment HCC risk, despite long-term antiviral treatment. Early initiation of antiviral treatment, tailored to viral load, should be considered to minimise HCC risk in adult CHB patients without cirrhosis.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Choi WM, Kim GA, Choi J, et al. Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B. Gut. 2024. PMID: 37813567. doi:10.1136/gutjnl-2023-330225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。